MX2017003589A - Compuestos de indolinona y usos de los mismos. - Google Patents
Compuestos de indolinona y usos de los mismos.Info
- Publication number
- MX2017003589A MX2017003589A MX2017003589A MX2017003589A MX2017003589A MX 2017003589 A MX2017003589 A MX 2017003589A MX 2017003589 A MX2017003589 A MX 2017003589A MX 2017003589 A MX2017003589 A MX 2017003589A MX 2017003589 A MX2017003589 A MX 2017003589A
- Authority
- MX
- Mexico
- Prior art keywords
- indolinone
- flll
- ews
- methods
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
Se proporcionan compuestos derivados de indolinona que actúan como inhibidores del factor de transcripción EWS-FLI1. También se proporcionan composiciones farmacéuticas de los derivados de indolinona, métodos para sintetizar los mismos, métodos de tratamiento que utilizan los mismos, y ensayos para identificar los inhibidores de oncoproteina EWS-FLI1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462062086P | 2014-10-09 | 2014-10-09 | |
PCT/US2015/054533 WO2016057698A1 (en) | 2014-10-09 | 2015-10-07 | Indolinone compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017003589A true MX2017003589A (es) | 2018-08-15 |
Family
ID=54337916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017003589A MX2017003589A (es) | 2014-10-09 | 2015-10-07 | Compuestos de indolinona y usos de los mismos. |
Country Status (14)
Country | Link |
---|---|
US (5) | US9604927B2 (es) |
EP (1) | EP3204376B1 (es) |
JP (2) | JP6654197B2 (es) |
KR (1) | KR102482197B1 (es) |
CN (2) | CN107108580B (es) |
AR (1) | AR102222A1 (es) |
AU (2) | AU2015328121B2 (es) |
CA (1) | CA2961781C (es) |
EA (1) | EA032644B1 (es) |
IL (2) | IL251498B (es) |
MX (1) | MX2017003589A (es) |
NZ (1) | NZ730585A (es) |
TW (2) | TWI750782B (es) |
WO (1) | WO2016057698A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013245812B2 (en) | 2012-04-12 | 2017-04-06 | Georgetown University | Methods and compositions for treating Ewing's sarcoma family of tumors |
US9604927B2 (en) | 2014-10-09 | 2017-03-28 | Oncternal Therapeutics, Inc. | Indolinone compounds and uses thereof |
US9822122B2 (en) * | 2016-03-31 | 2017-11-21 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
CA3029851A1 (en) * | 2016-07-29 | 2018-02-01 | Oncternal Therapeutics, Inc. | Uses of indoline compounds such as tk216 for the treatment of cancer |
CN110818611B (zh) * | 2018-08-13 | 2023-01-24 | 中国科学院上海药物研究所 | 一类吲哚酮类化合物、其制备方法、药物组合物和用途 |
EP4213838A2 (en) * | 2020-09-17 | 2023-07-26 | Oklahoma Medical Research Foundation | Inhibition of endothelial ets family transcription factors promotes flow-dependent ocular vessel regression |
CN113456631B (zh) * | 2021-08-06 | 2022-06-21 | 徐州医科大学 | 一种靶向acsl1的小分子药物及其在治疗子宫内膜癌中的应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3483704D1 (de) | 1983-07-22 | 1991-01-17 | Du Pont | Phenylchinolinsaeure und derivate als antitumormittel. |
AU1648600A (en) | 1998-12-04 | 2000-06-26 | Neurosearch A/S | Use of isatin derivatives as ion channel activating agents |
CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
AU2005323437B2 (en) | 2004-04-30 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a C5-modified pyrimidine |
AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
US20090217390A1 (en) | 2005-04-29 | 2009-08-27 | Fernando Lecanda Cordero | Non-human animal sarcoma model |
WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
CA2711003C (en) | 2006-12-29 | 2017-02-21 | Georgetown University | Targeting of ews-fli1 as anti-tumor therapy |
US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
ES2434693T3 (es) | 2007-04-20 | 2013-12-17 | The Research Foundation For The State University Of New York | Bencimidazoles y composiciones farmacéuticas de los mismos |
US8377992B2 (en) | 2007-10-22 | 2013-02-19 | The Wistar Institute | TRBD-binding effectors and methods for using the same to modulate telomerase activity |
JP6049260B2 (ja) * | 2008-10-10 | 2016-12-21 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | プロアポトーシスbax及びbcl−2ポリペプチドの化学モジュレータ |
PE20120059A1 (es) | 2008-10-21 | 2012-02-27 | Onyx Therapeutics Inc | Combinaciones farmaceuticas con epoxicetonas peptidicas |
US8710068B2 (en) | 2009-01-19 | 2014-04-29 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
WO2012078519A2 (en) * | 2010-12-06 | 2012-06-14 | Numerate, Inc. | 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 |
CN102516152B (zh) | 2011-12-12 | 2014-12-10 | 华东师范大学 | 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用 |
US20130259927A1 (en) | 2012-04-02 | 2013-10-03 | Gradalis, Inc. | Ewing's Sarcoma Bifunctional shRNA Design |
AU2013245812B2 (en) | 2012-04-12 | 2017-04-06 | Georgetown University | Methods and compositions for treating Ewing's sarcoma family of tumors |
WO2014015153A2 (en) | 2012-07-20 | 2014-01-23 | Star Biotechnology, Llc | Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1 |
US11285169B2 (en) * | 2013-03-13 | 2022-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
CN103435606A (zh) * | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
CN103613580B (zh) * | 2013-09-03 | 2016-02-10 | 遵义医学院 | 用于抗肿瘤药物的3-羟基吲哚-2-酮类化合物或其药学上能够接受的盐 |
KR20160065986A (ko) | 2013-10-24 | 2016-06-09 | 조지타운 유니버시티 | 암 치료용 방법 및 조성물 |
WO2015082583A1 (en) | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
US9604927B2 (en) | 2014-10-09 | 2017-03-28 | Oncternal Therapeutics, Inc. | Indolinone compounds and uses thereof |
US9822122B2 (en) | 2016-03-31 | 2017-11-21 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
CA3029851A1 (en) * | 2016-07-29 | 2018-02-01 | Oncternal Therapeutics, Inc. | Uses of indoline compounds such as tk216 for the treatment of cancer |
-
2015
- 2015-10-07 US US14/877,708 patent/US9604927B2/en active Active
- 2015-10-07 EA EA201790445A patent/EA032644B1/ru unknown
- 2015-10-07 CN CN201580054973.6A patent/CN107108580B/zh active Active
- 2015-10-07 CN CN202010495279.0A patent/CN111777596A/zh active Pending
- 2015-10-07 MX MX2017003589A patent/MX2017003589A/es unknown
- 2015-10-07 EP EP15784237.8A patent/EP3204376B1/en active Active
- 2015-10-07 NZ NZ730585A patent/NZ730585A/en unknown
- 2015-10-07 WO PCT/US2015/054533 patent/WO2016057698A1/en active Application Filing
- 2015-10-07 CA CA2961781A patent/CA2961781C/en active Active
- 2015-10-07 AU AU2015328121A patent/AU2015328121B2/en active Active
- 2015-10-07 JP JP2017538916A patent/JP6654197B2/ja active Active
- 2015-10-07 KR KR1020177012523A patent/KR102482197B1/ko active IP Right Grant
- 2015-10-08 TW TW109129160A patent/TWI750782B/zh active
- 2015-10-08 TW TW104133287A patent/TWI705054B/zh active
- 2015-10-09 AR ARP150103264A patent/AR102222A1/es unknown
-
2016
- 2016-11-21 US US15/357,933 patent/US9895352B2/en active Active
- 2016-11-21 US US15/357,876 patent/US9987251B2/en active Active
-
2017
- 2017-04-02 IL IL251498A patent/IL251498B/en unknown
-
2018
- 2018-05-07 US US15/973,110 patent/US20180256546A1/en not_active Abandoned
-
2019
- 2019-12-11 JP JP2019223835A patent/JP6795861B2/ja active Active
-
2020
- 2020-01-29 AU AU2020200631A patent/AU2020200631B2/en active Active
-
2021
- 2021-06-23 IL IL284322A patent/IL284322B2/en unknown
-
2022
- 2022-06-02 US US17/830,668 patent/US20220288023A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3642182A4 (en) | COMPOUNDS, COMPOSITIONS AND SYNTHESIS METHODS | |
PH12016502179A1 (en) | Inhibitors of lysine specific demethylase-1 | |
PH12017500509A1 (en) | Benzyl substituted indazoles as bub1 inhibitors | |
IL248915A0 (en) | Pyrrolidine-2,5-dione derivatives, preparations containing them and their use for the inhibition of ido1 | |
EP3610266A4 (en) | TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF | |
PH12016500739A1 (en) | Inhibitors of the fibrolast growth factor receptor | |
MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
PH12016501898B1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
MX2018003491A (es) | Represores de htt y usos de estos. | |
MX2017003589A (es) | Compuestos de indolinona y usos de los mismos. | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
EP3615657A4 (en) | APPARATUS, METHODS AND COMPOSITION FOR THE SYNTHESIS OF CANNABINOID COMPOUNDS | |
IL261015A (en) | History of methylamine as lysis oxidase inhibitors for cancer treatment | |
MX369369B (es) | Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
NZ725917A (en) | Novel polymerase-i inhibitors, uses and methods for making them | |
MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
TN2018000057A1 (en) | Compounds useful for inhibiting ror-gamma-t. | |
MX369473B (es) | Derivado de indolona sustituido por pirrol, método de preparación del mismo, composición que comprende el mismo y uso del mismo. | |
EA201691493A1 (ru) | Замещенные n-арилпиридиноны | |
MX2016015298A (es) | Inhibidores de nampt y metodos. | |
WO2018075598A8 (en) | SYNTHESIS OF EZH2 INHIBITORS |